目的对给予^(131)I 标记抗肝癌单克隆抗体(简称单抗)片段[HAb18F(ab)_2]的志愿者进行脏器内照射吸收剂量估算。方法 2例志愿者静脉注射^(131)I-HAb18F(ab)_2后,分别于5、30 min和2、4、8、24 h 及2、3、4、6、10 d 共11个时间点收集血样...目的对给予^(131)I 标记抗肝癌单克隆抗体(简称单抗)片段[HAb18F(ab)_2]的志愿者进行脏器内照射吸收剂量估算。方法 2例志愿者静脉注射^(131)I-HAb18F(ab)_2后,分别于5、30 min和2、4、8、24 h 及2、3、4、6、10 d 共11个时间点收集血样,并分别于治疗后3、24 h 和2、4、8、16 d 进行SPECT 全身显像;对血样进行放射性测量,测定全身平面图像感兴趣区(ROI)计数;应用 SPSS 13.0软件对获得的数据进行曲线拟合;计算药物在各脏器的有效半衰期;估算各脏器的吸收剂量。结果^(131)I-HAb18F(ab)_2在人体各脏器内的有效半衰期为1.8～6.4 d,甲状腺的吸收剂量最大为28.5 Gy,其余脏器不超过3 Gy。结论该计算方法简便易行,可应用于内照射吸收剂量的估算。展开更多
OBJECTIVE: To assess the efficacy of fractionated administration of radiolabeled monoclonal antibody in the treatment of metastases after tumor volume reduction surgery, various experimental therapies were studied com...OBJECTIVE: To assess the efficacy of fractionated administration of radiolabeled monoclonal antibody in the treatment of metastases after tumor volume reduction surgery, various experimental therapies were studied comparatively. METHODS: A total of 200 inbred mice received tumor implantation from a murine adenocarcinoma cell line. The mice were randomly grouped to give saline, Arc-a, 131I-C50 in single or fractionated doses, cold C50, or non-specific 131I-IgG with or without surgical removal of the implanted tumor xenograft. RESULTS: In comparison to controls, animals receiving Arc-a and radioactive agents had longer survival, smaller tumor, better clinical condition, and less metastases foci. The best therapeutic response was noted after fractionated doses of 131I-C50, which showed better results in every aspect than those treated with other modalities. The favorable outcome was even more pronounced after tumor volume reduction. CONCLUSIONS: Fractionated dosing may improve the deposition of radiolabeled monoclonal antibody (McAb) and provide the best therapeutic effect on implanted tumor and metastases. Thus fractionated radioimmunotherapy (RIT) after tumor volume reduction might be a practical method with promising therapeutic results.展开更多
To assess the intravesical application of immunotoxin as adjuvant therapy to prevent recurrence after tumor resection in bladder cancer patients Methods An anti human immunotoxin against bladder carcinoma, BDI 1 ...To assess the intravesical application of immunotoxin as adjuvant therapy to prevent recurrence after tumor resection in bladder cancer patients Methods An anti human immunotoxin against bladder carcinoma, BDI 1 RT, was prepared and its in vitro targeting cytotoxicity estimated The immunoreactivity of BDI 1 RT with human bladder cancer tissue of different grades and stages was detected by immunohistochemical analysis After safety test, intravesical administration of BDI 1 RT was performed in 31 patients while mitomycin C (MMC) was used in 36 patients serving as a control group The recurrence rates and side effects in both groups were recorded In addition, the development of human anti mouse antibodies (HAMA) was determined by ELISA, to assess the potential safety of this immuotoxin Results In our study, BDI 1 RT had immunoreactivity with 81 6% of bladder transitional cell carcinomas The immunoreactivity of BDI 1 RT correlated with tumor grade High grade carcinoma had stronger staining than low grade ( P <0 05) There was no significant difference between the BDI 1 RT group (10%) and MMC group (19 3%) in recurrence rate ( P >0 05) Side effects, including systemic and local, were more frequent in the MMC group (11 of 36 patients versus 2 of 31, P <0 05) HAMA was not detected in any of 7 patients Conclusion Immunotoxin may have considerable potential in the prophylaxis of bladder transition cell carcinoma展开更多
文摘目的对给予^(131)I 标记抗肝癌单克隆抗体(简称单抗)片段[HAb18F(ab)_2]的志愿者进行脏器内照射吸收剂量估算。方法 2例志愿者静脉注射^(131)I-HAb18F(ab)_2后,分别于5、30 min和2、4、8、24 h 及2、3、4、6、10 d 共11个时间点收集血样,并分别于治疗后3、24 h 和2、4、8、16 d 进行SPECT 全身显像;对血样进行放射性测量,测定全身平面图像感兴趣区(ROI)计数;应用 SPSS 13.0软件对获得的数据进行曲线拟合;计算药物在各脏器的有效半衰期;估算各脏器的吸收剂量。结果^(131)I-HAb18F(ab)_2在人体各脏器内的有效半衰期为1.8～6.4 d,甲状腺的吸收剂量最大为28.5 Gy,其余脏器不超过3 Gy。结论该计算方法简便易行,可应用于内照射吸收剂量的估算。
文摘OBJECTIVE: To assess the efficacy of fractionated administration of radiolabeled monoclonal antibody in the treatment of metastases after tumor volume reduction surgery, various experimental therapies were studied comparatively. METHODS: A total of 200 inbred mice received tumor implantation from a murine adenocarcinoma cell line. The mice were randomly grouped to give saline, Arc-a, 131I-C50 in single or fractionated doses, cold C50, or non-specific 131I-IgG with or without surgical removal of the implanted tumor xenograft. RESULTS: In comparison to controls, animals receiving Arc-a and radioactive agents had longer survival, smaller tumor, better clinical condition, and less metastases foci. The best therapeutic response was noted after fractionated doses of 131I-C50, which showed better results in every aspect than those treated with other modalities. The favorable outcome was even more pronounced after tumor volume reduction. CONCLUSIONS: Fractionated dosing may improve the deposition of radiolabeled monoclonal antibody (McAb) and provide the best therapeutic effect on implanted tumor and metastases. Thus fractionated radioimmunotherapy (RIT) after tumor volume reduction might be a practical method with promising therapeutic results.
基金hisworkwassupportedbythegrantsformtheScienceFoundationoftheMinistryofHealth China (No 970 2 0 15 )
文摘To assess the intravesical application of immunotoxin as adjuvant therapy to prevent recurrence after tumor resection in bladder cancer patients Methods An anti human immunotoxin against bladder carcinoma, BDI 1 RT, was prepared and its in vitro targeting cytotoxicity estimated The immunoreactivity of BDI 1 RT with human bladder cancer tissue of different grades and stages was detected by immunohistochemical analysis After safety test, intravesical administration of BDI 1 RT was performed in 31 patients while mitomycin C (MMC) was used in 36 patients serving as a control group The recurrence rates and side effects in both groups were recorded In addition, the development of human anti mouse antibodies (HAMA) was determined by ELISA, to assess the potential safety of this immuotoxin Results In our study, BDI 1 RT had immunoreactivity with 81 6% of bladder transitional cell carcinomas The immunoreactivity of BDI 1 RT correlated with tumor grade High grade carcinoma had stronger staining than low grade ( P <0 05) There was no significant difference between the BDI 1 RT group (10%) and MMC group (19 3%) in recurrence rate ( P >0 05) Side effects, including systemic and local, were more frequent in the MMC group (11 of 36 patients versus 2 of 31, P <0 05) HAMA was not detected in any of 7 patients Conclusion Immunotoxin may have considerable potential in the prophylaxis of bladder transition cell carcinoma
